Provided by Tiger Trade Technology Pte. Ltd.

BioRestorative Therapies, Inc.

0.2017
+0.00351.74%
Post-market: 0.1658-0.0359-17.80%19:59 EDT
Volume:489.29K
Turnover:99.19K
Market Cap:5.14M
PE:-0.19
High:0.2099
Open:0.2030
Low:0.2007
Close:0.1983
52wk High:1.86
52wk Low:0.1593
Shares:25.48M
Float Shares:23.76M
Volume Ratio:2.37
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0878
EPS(LYR):-1.5837
ROE:-241.14%
ROA:-118.81%
PB:1.70
PE(LYR):-0.13

Loading ...

Biorestorative Completes Phase 2 Manufacturing for Brtx-100 Lumbar Disc Disease Trial Supply

Reuters
·
Jun 25

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

GlobeNewswire
·
Jun 25

BioRestorative Therapies files Form 3 for director Jatinder Dhaliwal, reporting no beneficial ownership

Reuters
·
Jun 19

BioRestorative names Zachary Smith VP of biocosmeceuticals division

Reuters
·
Jun 18

BioRestorative Therapies Strengthens Leadership With Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

THOMSON REUTERS
·
Jun 18

BioRestorative Therapies director Katharyn Field files initial beneficial ownership statement

Reuters
·
Jun 18

BioRestorative adds lender designees Grasso, Field, Dhaliwal to board after three director resignations

Reuters
·
Jun 13

BioRestorative publishes investor presentation on BRTX-100 stem cell therapy for chronic lumbar disc disease

Reuters
·
Jun 02

BioRestorative names Lance Alstodt chairman, CEO and president under new employment deal

Reuters
·
May 30

BioRestorative Therapies shareholder Kaos Capital acquires 4.9% stake

TIPRANKS
·
May 27

Kaos Capital discloses 4.9% stake in BioRestorative Therapies

Reuters
·
May 27

Kaos Capital: Urgently Seeks Meeting With BioRestorative Therapies Board to Discuss Unlocking Shareholder Value

THOMSON REUTERS
·
May 27

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (Nasdaq: Brtx)

THOMSON REUTERS
·
May 27

BioRestorative Therapies completes Phase 2 dosing of BRTX-100

TIPRANKS
·
May 27

BioRestorative completes Phase 2 dosing of BRTX-100 in chronic lumbar disc disease trial, targets Q2 2027 data

Reuters
·
May 26

BioRestorative Therapies Inc - Topline Phase 2 Data for Brtx-100 Expected in Q2 2027

THOMSON REUTERS
·
May 26

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

GlobeNewswire
·
May 26

BioRestorative Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

BioRestorative Q1 FY26 net loss narrows to $2.15 million; revenue falls 7.32% to $23,170

Reuters
·
May 15

BioRestorative Therapies presents preclinical data on MSC exosome proteomics

TIPRANKS
·
May 14